Homologous recombination is the major biological mechanism underlying the gene correction and genetic modification using programmable nucleases such as CRISPR/Cas9. Currently the efficiency of homologous recombination remains low and is a bottleneck problem for gene editing. ATGC and University of Michigan co-developed miCas9 technology which can significantly improve the homologous recombination rate in CRIPSR/Cas9 mediated gene editing. ATGC was awarded this grant to continue developing the patented miCas9 technology, to demonstrate its power in the gene therapy of various genetic diseases. For details of the technology please search Project Number 2R42GM122181 in NIH RePORTER.
No comment